TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05063565
Drug: Tremelimumab immunotherapy
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg, single administration
Study: NCT05901649
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
Study: NCT05518149
Drug: Aticaprant
Normalized name: Aticaprant
DrugBank: Aticaprant (DB12341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aticaprant 10 mg tablet will be administered orally.
Study: NCT06222580
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06222580
Drug: Revumenib
Normalized name: Revumenib
DrugBank: Revumenib (DB18515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06138834
Drug: Low-dose Y-6 sublingual tablets
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
Study: NCT06138834
Drug: Low-dose Cilostazol
Normalized name: ethinyl estradiol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
Study: NCT06138834
Drug: High-dose Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
Study: NCT05713799
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selective beta3-AR agonist approved
Study: NCT05713799
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA is an antioxidant that is available over the counter
Study: NCT06233474
Drug: Allocetra
Normalized name: Allocetra
DrugBank: Allocetra (DB16424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state
Study: NCT00003502
Drug: antineoplaston A10
Normalized name: Antineoplaston A10
DrugBank: Antineoplaston A10 (DB11702)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003502
Drug: antineoplaston AS2-1
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05654298
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan 100 mg
Study: NCT05654298
Drug: Ubrogepant
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubrogepant 100 mg
Study: NCT06434233
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1
Study: NCT05006417
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: reconstituted at 100 units/mL, dosage will be based upon the affected muscles
Study: NCT05598606
Drug: Denosumab Injection
Normalized name: denosumab Injection
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
Study: NCT05598606
Drug: Zoledronate
Normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
Study: NCT05514548
Drug: INV-202
Normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
Study: NCT06028438
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab will be administered intravenously.
Study: NCT06028438
Drug: Certolizumab
Normalized name: certolizumab
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab will be administered subcutaneously.
Study: NCT06383403
Drug: Elafibranor
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round and orange film coated tablet of 80 mg.
Study: NCT05236231
Drug: Macitentan 10 mg
Normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 10mg tablet will be administered orally as per assigned treatment sequence.
Study: NCT05236231
Drug: Tadalafil 20 mg
Normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 20mg tablet will be administered orally as per assigned treatment sequence.
Study: NCT05236231
Drug: Macitentan 10 mg/Tadalafil 20mg FDC
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDC of Macitentan 10 mg/Tadalafil 20 mg will be administered orally as single dose tablets.
Study: NCT06457503
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
Study: NCT06457503
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
Study: NCT06457503
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
Study: NCT06457503
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
Study: NCT05094336
Drug: AMG 193
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 193: Orally via tablet
Study: NCT05094336
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel: Intravenous infusion
Study: NCT06457789
Drug: [89Zr]Zr-Df-Crefmirlimab PET imaging
DrugBank: Crefmirlimab (DB17577)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.
Study: NCT05923047
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
Study: NCT06425991
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered subcutaneously.
Study: NCT06150157
Drug: JNJ-88549968
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-88549968 will be administered.
Study: NCT05867121
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Study: NCT06121401
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
Study: NCT06121401
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
Study: NCT05867121
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 will be administered as per the schedules specified in the respective arms.
Study: NCT05867121
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered as per the schedules specified in the respective arms.
Study: NCT05867121
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered as per the schedules specified in the respective arms.
Study: NCT05867121
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered as per the schedules specified in the respective arms.
Study: NCT05867121
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered as per the schedules specified in the respective arms.
Study: NCT06382948
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 7.5 mg of everolimus orally once daily.
Study: NCT06382948
Drug: Elacestrant
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive elacestrant 345 mg orally once daily
Study: NCT06382948
Drug: Auxiliary Medicinal Product - Dexamethasone
Normalized name: dexamethasone Injectable Product
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
Study: NCT06382948
Drug: Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.
Study: NCT06003218
Drug: Dexmedetomidine-esketamine combination
Normalized name: esketamine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
Study: NCT06003218
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone will be injected intravenously 10-15 min before puncture.
Study: NCT05754957
Drug: Milvexian
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian will be administered orally.
Study: NCT05483907
Drug: BBT-877
Normalized name: BBT-877
DrugBank: BBT-877 (DB18668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBT-877 24 weeks + Follow-up 4 weeks
Study: NCT05564377
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05564377
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05764590
Drug: AP-306
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A blood phosphorus lowering drug with a novel mechanism
Study: NCT05764590
Drug: Sevelamer Carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A phosphate binder
Study: NCT05004311
Drug: Cenerimod
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
Study: NCT04107077
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
Study: NCT05564377
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IM
Study: NCT05564377
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05564377
Drug: Neratinib Maleate
Normalized name: Neratinib Maleate
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05564377
Drug: Nilotinib Hydrochloride Monohydrate
Normalized name: NILOTINIB HYDROCHLORIDE MONOHYDRATE
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05564377
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05564377
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05564377
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO or IV
Study: NCT05564377
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05564377
Drug: Selumetinib Sulfate
Normalized name: selumetinib sulfate
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05564377
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05554367
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05554367
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04107077
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
Study: NCT04514692
Drug: GCSF
Normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte Colony Stimulating Factor (GCSF)
Study: NCT05268601
Drug: Bamlanivimab
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of monoclonal antibody against SARS-CoV-2
Study: NCT05268601
Drug: Bamlanivimab and Etesevimab Drug Combination
Normalized name: Etesevimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined administration of monoclonal antibodies against SARS-CoV-2
Study: NCT05268601
Drug: Casirivimab and Imdevimab Drug Combination
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined administration of monoclonal antibodies against SARS-CoV-2
Study: NCT05268601
Drug: Sotrovimab
Normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Administration of monoclonal antibody against SARS-CoV-2
Study: NCT05272150
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive guselkumab as subcutaneous injection.
Study: NCT05696626
Drug: Lasofoxifene in combination with abemaciclib
DrugBank: Lasofoxifene (DB06202)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
Study: NCT05696626
Drug: Fulvestrant in combination with abemaciclib
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
Study: NCT06295692
Drug: JNJ-77242113
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 tablet will be administered orally.
Study: NCT05913973
Drug: Pvs230D1-EPA/Matrix-M
DrugBank: Matrix-M (DB16369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
Study: NCT06312137
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
Study: NCT06312137
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
Study: NCT06312137
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
Study: NCT06312137
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
Study: NCT06312137
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
Study: NCT04402788
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06567015
Drug: STX-241
Normalized name: STX-100
DrugBank: STX-100 (DB16334)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet~Route of administration: Oral
Study: NCT05815160
Drug: Debio 0123
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as capsules.
Study: NCT05815160
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as IV infusion.
Study: NCT05815160
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as IV infusion.
Study: NCT04885634
Drug: Semaglutide Injectable Product
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection of Semaglutide 2.4 mg once weekly
Study: NCT04540744
Drug: FDC of macitentan/tadalafil (10 mg/20 mg)
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
Study: NCT04540744
Drug: Macitentan 10 mg
Normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
Study: NCT04540744
Drug: Tadalafil 20 mg
Normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
Study: NCT06177301
Drug: Tislelizumab combined with GX
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.